Header Logo

Connection

WOLFGANG WINKELMAYER to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Cardiovascular Diseases.
WOLFGANG WINKELMAYER
Connection Strength
2.765
Cardiovascular Diseases
  1. Associations of Glycemic Control With Cardiovascular Outcomes Among US Hemodialysis Patients With Diabetes Mellitus. J Am Heart Assoc. 2017 Jun 07; 6(6).
    View in: PubMed
    Score: 0.239
  2. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis. Nephrol Dial Transplant. 2017 May 01; 32(5):862-869.
    View in: PubMed
    Score: 0.237
  3. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis. J Nephrol. 2017 Apr; 30(2):281-288.
    View in: PubMed
    Score: 0.225
  4. Use of secondary prevention medications among adults with reduced kidney function. Clin J Am Soc Nephrol. 2012 Apr; 7(4):604-11.
    View in: PubMed
    Score: 0.165
  5. Altitude and the risk of cardiovascular events in incident US dialysis patients. Nephrol Dial Transplant. 2012 Jun; 27(6):2411-7.
    View in: PubMed
    Score: 0.164
  6. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J. 2011 Aug; 162(2):324-30.
    View in: PubMed
    Score: 0.159
  7. Cardiovascular risk and the thiazolidinediones: d?j? vu all over again? JAMA. 2007 Sep 12; 298(10):1216-8.
    View in: PubMed
    Score: 0.122
  8. Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making. 2006 May-Jun; 26(3):247-54.
    View in: PubMed
    Score: 0.111
  9. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes Obes Metab. 2022 05; 24(5):928-937.
    View in: PubMed
    Score: 0.083
  10. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant. 2021 01 01; 36(1):129-136.
    View in: PubMed
    Score: 0.076
  11. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease. Expert Opin Investig Drugs. 2000 Nov; 9(11):2637-51.
    View in: PubMed
    Score: 0.076
  12. Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrol Dial Transplant. 2020 10 01; 35(10):1761-1769.
    View in: PubMed
    Score: 0.075
  13. Re-estimation improved the performance of two Framingham cardiovascular risk equations and the Pooled Cohort equations: A nationwide registry analysis. Sci Rep. 2020 05 18; 10(1):8140.
    View in: PubMed
    Score: 0.073
  14. Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. Am J Kidney Dis. 2020 07; 76(1):109-120.
    View in: PubMed
    Score: 0.073
  15. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. 2020 02 01; 35(2):312-319.
    View in: PubMed
    Score: 0.072
  16. Trends in the Medical Complexity and Outcomes of Medicare-insured Patients Undergoing Kidney Transplant in the Years 1998-2014. Transplantation. 2019 11; 103(11):2413-2422.
    View in: PubMed
    Score: 0.071
  17. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020 01; 97(1):42-61.
    View in: PubMed
    Score: 0.070
  18. Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014). Am J Nephrol. 2018; 48(6):472-481.
    View in: PubMed
    Score: 0.066
  19. External validation of two Framingham cardiovascular risk equations and the Pooled Cohort equations: A nationwide registry analysis. Int J Cardiol. 2019 05 15; 283:165-170.
    View in: PubMed
    Score: 0.066
  20. Cardiovascular Outcomes Reported in Hemodialysis Trials. J Am Coll Cardiol. 2018 06 19; 71(24):2802-2810.
    View in: PubMed
    Score: 0.064
  21. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex. Am J Kidney Dis. 2017 Jun; 69(6):771-779.
    View in: PubMed
    Score: 0.058
  22. Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis. Arthritis Care Res (Hoboken). 2015 Oct; 67(10):1453-62.
    View in: PubMed
    Score: 0.053
  23. Kidney Function and Cardiovascular Events in Postmenopausal Women: The Impact of Race and Ethnicity in the Women's Health Initiative. Am J Kidney Dis. 2016 Feb; 67(2):198-208.
    View in: PubMed
    Score: 0.053
  24. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
    View in: PubMed
    Score: 0.052
  25. State medicaid coverage, ESRD incidence, and access to care. J Am Soc Nephrol. 2014 Jun; 25(6):1321-9.
    View in: PubMed
    Score: 0.048
  26. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One. 2013; 8(11):e78930.
    View in: PubMed
    Score: 0.047
  27. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005 Dec; 46(6):1080-7.
    View in: PubMed
    Score: 0.027
  28. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transplant. 2004 Aug; 18(4):341-8.
    View in: PubMed
    Score: 0.025
  29. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
    View in: PubMed
    Score: 0.020
  30. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
    View in: PubMed
    Score: 0.020
  31. Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1-5. Hypertension. 2021 03 03; 77(3):948-959.
    View in: PubMed
    Score: 0.019
  32. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol. 2018 Jul - Aug; 12(4):1061-1071.e7.
    View in: PubMed
    Score: 0.016
  33. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol. 2016 Oct; 27(10):3129-3138.
    View in: PubMed
    Score: 0.014
  34. Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. Transplantation. 2013 Jun 15; 95(11):1338-45.
    View in: PubMed
    Score: 0.011
  35. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clin Nephrol. 2012 Sep; 78(3):181-8.
    View in: PubMed
    Score: 0.011
  36. Anaemia after renal transplantation. Eur J Clin Invest. 2005 Dec; 35 Suppl 3:89-94.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.